The Omnicell Inc. (OMCL) Now Covered by Analysts at Dougherty & Co

The Omnicell Inc. (OMCL) Now Covered by Analysts at Dougherty & Co

Dougherty & Co began coverage on shares of Omnicell Inc. (NASDAQ:OMCL) in a report issued on Thursday. The firm set a “buy” rating and a $44.00 price target on the stock. Dougherty & Co’s price target points to a potential upside of 34.76% from the company’s current price.

Other analysts also recently issued reports about the stock. TheStreet downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Benchmark Co. upped their target price on shares of Omnicell from $39.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, December 6th. Cantor Fitzgerald started coverage on shares of Omnicell in a research report on Thursday, January 5th. They issued an “overweight” rating and a $40.00 target price on the stock. Finally, Oppenheimer Holdings Inc. set a $46.00 target price on shares of Omnicell and gave the stock a “buy” rating in a research report on Thursday, October 27th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $42.44.

Shares of Omnicell (NASDAQ:OMCL) opened at 32.65 on Thursday. The company’s 50-day moving average is $33.73 and its 200-day moving average is $35.62. Omnicell has a 12-month low of $25.06 and a 12-month high of $40.50. The stock has a market cap of $1.19 billion, a P/E ratio of 149.77 and a beta of 0.69.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, October 27th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.41 by $0.01. The company had revenue of $179.40 million for the quarter, compared to analysts’ expectations of $179.75 million. Omnicell had a net margin of 1.24% and a return on equity of 10.74%. The firm’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.36 earnings per share. On average, equities research analysts anticipate that Omnicell will post $1.55 earnings per share for the current year.

In other Omnicell news, VP J Christopher Drew sold 20,000 shares of the company’s stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $31.95, for a total transaction of $639,000.00. Following the transaction, the vice president now owns 139,844 shares in the company, valued at approximately $4,468,015.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jorge R. Taborga sold 2,068 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $33.66, for a total transaction of $69,608.88. Following the transaction, the vice president now owns 47,223 shares in the company, valued at approximately $1,589,526.18. The disclosure for this sale can be found here. Company insiders own 3.75% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Texas Permanent School Fund boosted its position in Omnicell by 0.3% in the third quarter. Texas Permanent School Fund now owns 27,548 shares of the company’s stock valued at $1,055,000 after buying an additional 84 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in Omnicell by 0.6% in the third quarter. Louisiana State Employees Retirement System now owns 16,000 shares of the company’s stock valued at $613,000 after buying an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in Omnicell by 1.7% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,970 shares of the company’s stock valued at $305,000 after buying an additional 130 shares in the last quarter. Eqis Capital Management Inc. boosted its position in Omnicell by 1.9% in the third quarter. Eqis Capital Management Inc. now owns 9,339 shares of the company’s stock valued at $358,000 after buying an additional 176 shares in the last quarter. Finally, PineBridge Investments L.P. boosted its position in Omnicell by 4.0% in the second quarter. PineBridge Investments L.P. now owns 4,555 shares of the company’s stock valued at $156,000 after buying an additional 177 shares in the last quarter. Institutional investors and hedge funds own 93.79% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

Related posts

Leave a Comment